CD274 and non-small cell lung carcinoma: For the KEYNOTE-091 trial (59), the results from interim analysis showed that DFS was significantly improved in stage IB-IIIA NSCLC patients receiving pembrolizumab compared with those receiving placebo, regardless of PD-L1 expression (53.6 months vs. 42.0 months; HR=0.76; 95% CI: 0.63-0.91).